All In Biotech

Drug Trial Radar · NCT04606446

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

320

Planned (sponsor's estimate)

Start

Nov 16, 2020

Primary completion

Aug 27, 2029

Study completion Aug 27, 2029

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other agents

Conditions

  • Locally Advanced or Metastatic ER+ HER2- Breast Cancer
  • Locally Advanced or Metastatic Castration-resistant Prostate Cancer
  • Locally Advanced or Metastatic Non-small Cell Lung Cancer

Interventions

  • PF-07248144Drug

    KAT6 Inhibitor

  • FulvestrantDrug

    Endocrine Therapy

  • LetrozoleDrug

    Endocrine Therapy

  • PalbociclibDrug

    CDK4/6 Inhibitor

  • PF-07220060Drug

    CDK4 inhibitor

  • PF-07850327, ARV-471, vepdegestrantDrug

    PROTAC (PROteolysis Targeting Chimera) ER degrader

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose-limiting toxicities in the Dose Escalation Arms.Time frame: Up to 29 days
  2. Safety and Tolerability as assessed by adverse event monitoring for participants enrolled in the Dose Escalation Arms.Time frame: Up to 24 months
  3. Safety and Tolerability through monitoring of laboratory assessments for participants enrolled in the Dose Escalation Arms.Time frame: Up to 24 months
  4. Safety and Tolerability as assessed by adverse event monitoring for participants enrolled in the Dose Expansion ArmsTime frame: Up to 24 months
  5. Safety and Tolerability through monitoring of laboratory assessments for participants enroled in the Dose Expansion ArmsTime frame: Up to 24 months

Locations

43 sites in 5 countries. Site status is shown where the registry gives one.

  • HonorHealth

    Scottsdale, Arizona · Terminated

  • Cedars-Sinai Cancer at Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • UCSF Medical Center at Mission Bay

    San Francisco, California · Recruiting

  • Smilow Cancer Hospital at Yale - New Haven

    New Haven, Connecticut · Recruiting

  • Yale-New Haven Hospital- Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Smilow Cancer Hospital Phase 1 Unit

    New Haven, Connecticut · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • Holy Cross Hospital

    Fort Lauderdale, Florida · Terminated

  • St. Elizabeth Healthcare

    Edgewood, Kentucky · Recruiting

  • University Medical Center, lnc.:DBA University of Louisville Hospital

    Louisville, Kentucky · Recruiting

  • University of Louisville

    Louisville, Kentucky · Recruiting

  • UofL Health Brown Cancer Center

    Louisville, Kentucky · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • MD Anderson The Woodlands

    Conroe, Texas · Recruiting

  • The University of Texas M. D. Anderson Cancer Center

    Houston, Texas · Recruiting

  • U.T. MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • MD Anderson West Houston

    Houston, Texas · Recruiting

  • MD Anderson League City

    League City, Texas · Recruiting

  • NEXT Oncology

    San Antonio, Texas · Recruiting

  • MD Anderson

    Sugar Land, Texas · Recruiting

  • Swedish Cancer Institute

    Seattle, Washington · Recruiting

  • Swedish Medical Center

    Seattle, Washington · Recruiting

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia · Terminated

  • Cancer Research South Australia

    Adelaide, South Australia, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia · Recruiting

  • Western Health-Sunshine & Footscray Hospitals

    St Albans, Victoria, Australia · Recruiting

  • St. John of God Subiaco Hospital

    Subiaco, Western Australia, Australia · Recruiting

  • Beijing Cancer hospital

    Beijing, Beijing Municipality, China · Recruiting

  • SUN Yat-Sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • Jilin Province Tumor Hospital

    Changchun, Jilin, China · Recruiting

  • Jilin Province Tumor Hospital

    Changchun, Jilin, China · Recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China · Recruiting

  • Aichi Cancer Center Hospital

    Nagoya, Aichi-ken, Japan · Recruiting

  • National Cancer Center Hospital East

    Kashiwa, Chiba, Japan · Recruiting

  • Kanagawa cancer center

    Yokohama, Kanagawa, Japan · Recruiting

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, Japan · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Recruiting

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, Seoul-teukbyeolsi [seoul], South Korea · Recruiting

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.